Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE revises hepatitis C treatments

  • Comment

NICE is updating recommendations advocating wider drug use for treating chronic hepatitis C patients.

The Health Protection Agency reports that approximately 142,000 people between 15 to 59 years old suffer from chronic hepatitis C in Wales and England.

Combination therapies are being recommended by NICE, including the drugs peginterferon alfa (2a or 2b) and ribavirin. The recommendation applies to those who have been treated unsuccessfully by either drug or who also suffer from HIV.

Dr Gillian Leng, NICE Deputy Chief Executive, said: “Chronic hepatitis C can be a debilitating condition, which, if left untreated can lead to serious life-long health consequences.

“However, the treatments themselves do have some side effects, which is why this draft guidance is good news for people who want to consider taking shorter courses of treatment with peginterferon alfa. Widening access to these drugs will not increase the NHS drug budget by much but will give clinicians and people living with hepatitis C more treatment options.“

The draft guidance is currently being reviewed to later be adopted by the NHS.

The draft guidance is available on the NICE website

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs